Vaccine Immunotherapy for Prostate Cancer
Annual rept. 15 Apr 2009-14 Apr 2010, Phase 2
IOWA UNIV IOWA CITY
Pagination or Media Count:
The purpose of the research supported by this award is to conduct a Phase II clinical trial Study of an adenovirusPSA AdPSA vaccine for the treatment of prostate cancer. Two protocols are being used in the trial 1 - Phase II study of adenovirusPSA vaccine in men with recurrent prostate cancer after local therapy, and 2 - Phase II study of adenovirusPSA vaccine in men with hormone refractory prostate cancer. In the first protocol men with recent documentation of recurrent prostate cancer are randomized to one of two arms of the study. Patients in Arm A receive the AdPSA vaccine only three injections spaced 30 days apart. Patients in Arm B will receive androgen deprivation therapy ADT followed at day 14 by the first of three AdPSA injections. In the second protocol men with hormone refractory prostate cancer are injected with the vaccine only, three injections 30 days apart. The patients are followed for toxicity, the development of anti-PSA immune responses, and evidence of a clinical effect of the vaccination. The latter includes changes in serum PSA and prostatic acid phosphatase PAP, and the PSA doubling times PSADT. Patients in protocol 2 also have CT and bone scans to monitor their prostate cancer.
- Medicine and Medical Research